Full-Time

AI Engineer

Posted on 8/22/2025

Pattern Bioscience

Pattern Bioscience

51-200 employees

AI-driven rapid bacterial ID and AST

No salary listed

Lehi, UT, USA

Hybrid

This is a hybrid role, which typically means a mix of in-office and remote work.

Category
AI & Machine Learning (3)
, ,
Required Skills
FastAPI
Python
AWS
Requirements
  • 3-5 years of post-college experience beyond internships in AI engineering roles at US firms.
  • An absolute obsession with learning about LLMs and AIs, balanced with an understanding of when NOT to use LLMs to solve problems (using AI as an accelerant vs as a crutch).
  • Strong python programming skills, helpful if familiar with libraries such as FastAPI, Pydantic, Streamlit, etc.
  • Good grasp of core software engineering principles such as SOLID, CI/CD, type checking and linting, etc.
  • Understand cloud architecture in AWS (S3, DynamoDB, RDS, ECS/EC2, etc).
  • Experience with generative AI models and tools (OpenAI, Anthropic, Bedrock, etc).
Responsibilities
  • Assist with developing AI workflows and agentic patterns, using platforms like n8n, MCP, and other agentic frameworks and services.
  • You will be tasked to venture beyond the foundational AI layer and assist with building and fixing AI workflows and agentic patterns that solve problems across Pattern.
  • In other cases, you’ll operate as an advisor for others who are building those AI workflows, providing guidance on how the foundational AI layer works and advising on best practices.
  • Training and creating educational resources for the company.
  • Hold training sessions with other teams and introduce them to new tools and best practices.
  • Create documentation and training materials to help people quickly learn how to use AI tools that you build and maintain.
  • Add functionality to our internal chat site, powered by Open WebUI.
  • Develop new experimental features and integrations.
  • Identify successful features and help migrate them into more stable applications across Pattern.
  • Maintain and expand our FastAPI proxy gateway router that connects to external AI providers, and associated SDK.
  • Improve the reliability of the platform by fixing bugs, adding fallback functionality, etc.
  • Expand the number of models and providers available in the platform.
  • Widen the range of functionality offered by the platform with greater levels of control and flexibility.
Desired Qualifications
  • Game Changers- A game changer is someone who looks at problems with an open mind and shares new ideas with team members, regularly reassesses existing plans and attaches a realistic timeline to goals, makes profitable, productive, and innovative contributions, and actively pursues improvements to Pattern’s processes and outcomes.
  • Data Fanatics- A data fanatic is someone who recognizes problems and seeks to understand them through data, draws unbiased conclusions based on data that lead to actionable solutions, and continues to track the effects of the solutions using data.
  • Partner Obsessed- An individual who is partner obsessed clearly explains the status of projects to partners and relies on constructive feedback, actively listens to partner’s expectations, and delivers results that exceed them, prioritizes the needs of your partners, and takes the time to create a personable experience for those interacting with Pattern.
  • Team of Doers- Someone who is a part of a team of doers uplifts team members and recognizes their specific contributions, takes initiative to help in any circumstance, actively contributes to supporting improvements, and holds themselves accountable to the team as well as to partners.

Pattern Bioscience develops rapid clinical diagnostics that identify bacterial infections and determine antibiotic resistance. Its system uses single-cell analysis with AI pattern recognition to deliver definitive ID/AST results in about four hours. The product suite includes diagnostic devices, consumables, service contracts, and software for AI analysis. By speeding and improving accuracy, Pattern Bioscience aims to help hospitals reduce inappropriate antibiotic use and combat antibiotic resistance.

Company Size

51-200

Company Stage

Series D

Total Funding

$91.6M

Headquarters

Austin, Texas

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • $43M Series D funding from AMR Action Fund supports FDA 510(k) submission.
  • $40.9M BARDA contract accelerates pneumonia and bacteremia panel development.
  • Over 1,000 samples enrolled in multi-center trial for Q3 regulatory push.

What critics are saying

  • Accelerate Diagnostics' PhenoVue captures market with FDA-cleared 3-hour AST.
  • BioFire's FilmArray dominates ICU syndromic testing, sidelining single-pathogen focus.
  • Clinical trial failure by mid-2026 exhausts Series D runway, halting launch.

What makes Pattern Bioscience unique

  • Digital CultureTM enables culture-free phenotypic ID/AST in four hours.
  • Single-cell analysis captures all resistance mechanisms unlike genotypic tests.
  • Pneumonia ID/AST Panel targets critically ill patients with FDA Breakthrough Designation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

-1%
Legal Desire
Nov 19th, 2025
Pattern Bioscience Raises $43M Series D

Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.

VCBay
Apr 29th, 2023
Austin-based Biotech startup Pattern Bioscience raises USD 28.7 million in Series C funding

To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology.

Business Wire
Apr 28th, 2023
Pattern Bioscience Secures $28.7 Million in Series C Financing

Pattern Bioscience secures $28.7 million in Series C financing to accelerate development of first-of-its-kind infectious disease diagnostic platform

FinSMEs
Apr 27th, 2023
Pattern Bioscience Raises $28.7M in Series C Financing

Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.

360Dx
Apr 27th, 2023
Pattern Bioscience Closes $28.7M Series C Financing Round | 360Dx

Including the Series C round, Pattern has now raised $68 million to date, the company said in a statement.

INACTIVE